11:41 AM EDT, 03/11/2024 (MT Newswires) -- Acelyrin ( SLRN ) said Monday that the phase 2b/3 clinical trial of its izokibep product candidate in psoriatic arthritis met the primary endpoint at week 16 with "high statistical significance."

The company said trial results also showed improved magnitude of responses on higher hurdle endpoints and minimal disease activity relative to phase 2 dose.

In a separate statement, the firm said 32-week data from a phase 2b trial of izokibep in hidradenitis suppurativa showed no evidence of increased safety liability with longer-term treatment and longer therapy duration was associated with further clinical improvements over time.

The company said topline data from an ongoing phase 3 trial of izokibep in hidradenitis suppurativa is expected by the end of the year and that it plans a confirmatory phase 3 trial that will enlist about 400 patients.

The shares were up more than 11% in recent trading.

Price: 8.37, Change: +0.89, Percent Change: +11.90